Revelation Biosciences, Inc. (REVB)

Revelation Biosciences' stock price has experienced significant declines over the past six months. The company implemented a 1-for-4 reverse stock split effective January 28, 2026, following a 1-for-16 reverse stock split in January 2025. In January 2026, they announced an agreement for warrant exercises, raising $11 million, and filed for a 4.27 million share offering. In December 2024, warrant exercises raised $4 million, and a secondary offering of common stock was filed. In January 2026, an agreement with the FDA was reached regarding the approval pathway for their acute kidney injury drug candidate, and GMP manufacturing began for GEMINI drug and placebo. In November 2025, the company was on track for an End-of-Phase 1 meeting with the FDA. Financial results for the three and nine months ended September 30, 2025, were reported, including top-line PRIME clinical study results and $12.7 million in cash. Nasdaq granted Revelation Biosciences' request for continued listing in January 2025.

Revelation Biosciences' products do not typically exhibit traditional demand seasonality. Demand for their therapeutic candidates is primarily driven by clinical trial progress, regulatory approvals, and the prevalence of the conditions they aim to treat, rather than seasonal fluctuations. While some respiratory diagnostic products might see increased usage during cold and flu seasons, overall demand seasonality for its pipeline products is not a significant factor.

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic-based therapies for disease prevention and treatment. Their therapeutic platform centers on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD) to rebalance the innate immune system. Key product candidates include GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease, REVTx-99b for allergic rhinitis and chronic nasal congestion, REVDx 501 for rapid respiratory viral infection detection, REVTx 200 as an intranasal immunomodulator adjunct for intramuscular vaccination, GEM-SSI for surgical site infection, and GEM-PBI for severe burn-related hyperinflammation.

Revelation Biosciences, Inc. is headquartered in San Diego, California, United States, with operations and market focus primarily within the United States.

Revelation Biosciences' brand reputation has been negatively impacted by its poor stock performance and analyst sentiment. The stock has experienced catastrophic declines, and analysts have a "Sell" consensus rating for the company. This bearish sentiment contributes to a negative perception of the company's financial health and prospects. Revelation Biosciences scored higher than 23% of companies evaluated by MarketBeat's MarketRank™.

Revelation Biosciences' stock is distributed among institutional investors (6.17%), insiders (40.92%), and public/individual investors (52.91%). Major institutional shareholders include Sabby Management, LLC, Armistice Capital, LLC, DRW Securities, LLC, Vanguard Group Inc, Jane Street Group, LLC, UBS Group AG, Tower Research Capital LLC (TRC), Bank Of America Corp /de/, Citigroup Inc, and Danske Bank A/s. James Rolke, the CEO, owns the most shares among individual investors, holding 2.11% of the company's shares.